{"id":"NCT02791516","sponsor":"Amgen","briefTitle":"A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Postmenopausal South Korean Women With Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-16","primaryCompletion":"2018-02-12","completion":"2018-12-21","firstPosted":"2016-06-06","resultsPosted":"2019-07-05","lastUpdate":"2019-10-07"},"enrollment":67,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Osteoporosis"],"interventions":[{"type":"DRUG","name":"Romosozumab","otherNames":["AMG 785","Evenity"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Romosozumab","type":"EXPERIMENTAL"}],"summary":"The primary objective is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual-energy X-ray absorptiometry (DXA) in postmenopausal women with osteoporosis.","primaryOutcome":{"measure":"Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine","timeFrame":"Baseline and month 6","effectByArm":[{"arm":"Placebo","deltaMin":-0.1,"sd":0.8},{"arm":"Romosozumab 210 mg","deltaMin":9.5,"sd":0.9}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"55 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":10,"countries":["South Korea"]},"refs":{"pmids":["33677928"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":33},"commonTop":["Nasopharyngitis","Back pain"]}}